Merrimack Pharmaceuticals
MACK
#8376
Rank
A$0.33 B
Marketcap
A$22.70
Share price
0.00%
Change (1 day)
-1.63%
Change (1 year)

Earnings for Merrimack Pharmaceuticals (MACK)

Earnings in 2024 (TTM): -A$3.43 Million

According to Merrimack Pharmaceuticals's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -A$3.27 Million a decrease over its 2022 earnings that were of -A$3.27 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Merrimack Pharmaceuticals from 2010 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$3.43 Million4.86%
2023 -A$3.27 Million0.09%
2022 -A$3.27 Million-16.9%
2021 -A$3.93 Million-49.89%
2020 -A$7.84 Million-75.39%
2019 -A$31.83 Million-68.58%
2018 -A$0.11 Billion-19.4%
2017 -A$0.13 Billion-36.46%
2016 -A$0.2 Billion2.54%
2015 -A$0.2 Billion96.78%
2014 -A$98.01 Million-45.44%
2013 -A$0.18 Billion
2010 -A$69.66 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$13.65 B-402,944.62%๐Ÿ‡ซ๐Ÿ‡ท France
AVEO Oncology
AVEO
-A$43.57 Million 1,185.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
-A$68.9 Million 1,932.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Clovis Oncology
CLVS
-A$0.33 Billion 9,523.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-A$14.24 Million 320.05%๐Ÿ‡บ๐Ÿ‡ธ USA